Bristol Myers to buy heart drug developer MyoKardia for about $13 billion By Reuters

2/2
© Reuters. BRISTOL-MYERS

2/2

(Reuters) – Bristol Myers Squibb Co (N:) said on Monday it would buy MyoKardia Inc (O:) for about $13 billion to bolster its portfolio of heart disease treatments, as it seeks to reduce some of its dependence on cancer drugs.

The deal follows Bristol Myers’ $74 billion acquisition of Celgene Corp (NASDAQ:) last year that combined two of the world’s largest cancer drug businesses in the biggest pharmaceutical deal ever.

Shares of MyoKardia, which have nearly doubled in value this year, surged another 58.5% to $221.25 before the opening bell, just shy of Bristol Myers’ offer price of $225 per share.

With the deal, Bristol Myers gains mavacamten, an experimental heart disease therapy with blockbuster potential.

The drug is being tested for treating obstructive hypertrophic cardiomyopathy – a disease where a heart muscle thickens and obstructs blood flow. It affects up to 200,000 people across the United States and Europe.

“I think it is a typical acquisition premium for our sales expectations for mavacamten as we had estimates in the initial (and lowest risk) indication of obstructive hypertrophic cardiomyopathy of about $2.5 billion by 2026,” Wedbush analyst David Nierengarten said.

Brsitol Myers said the acquisition provides a “medium- and long-term growth driver” and will add to its earnings beginning in 2023, a year after its top-selling cancer drug Revlimid is expected to lose some of its patent exclusivity in the United States.

Sales of its blockbuster immunotherapy Opdivo have been eclipsed by Merck & Co ‘s (N:) Keytruda, which has received approvals to treat newly diagnosed forms of advanced lung cancer.

Myokardia is expected to submit a marketing application for mavacamten to the U.S. health regulator in the first quarter of 2021.

Bristol Myers said it expects to explore the use of mavacamten for other diseases and develop MyoKardia’s portfolio of experimental drugs.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*